4.7 Article

Anticancer Peptides Derived from Aldolase A and Induced Tumor-Suppressing Cells Inhibit Pancreatic Ductal Adenocarcinoma Cells

Journal

PHARMACEUTICS
Volume 15, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics15102447

Keywords

pancreatic ductal carcinoma; peptide; ALDOA; induced tumor-suppressing cells

Ask authors/readers for more resources

This research identified an anticancer peptide P04 derived from aldolase A (ALDOA) which showed efficient anti-PDAC activities. P04 interacted with epidermal growth factor receptor (EGFR) and downregulated oncoproteins such as Snail and Src. Furthermore, P04 had no inhibitory effect on mesenchymal stem cells (MSCs). The study also demonstrated the potential of converting peripheral blood mononuclear cells (PBMCs) into induced tumor-suppressing cells (iTSCs) through mechanical vibration.
PDAC (pancreatic ductal adenocarcinoma) is a highly aggressive malignant tumor. We have previously developed induced tumor-suppressing cells (iTSCs) that secrete a group of tumor-suppressing proteins. Here, we examined a unique procedure to identify anticancer peptides (ACPs), using trypsin-digested iTSCs-derived protein fragments. Among the 10 ACP candidates, P04 (IGEHTPSALAIMENANVLAR) presented the most efficient anti-PDAC activities. P04 was derived from aldolase A (ALDOA), a glycolytic enzyme. Extracellular ALDOA, as well as P04, was predicted to interact with epidermal growth factor receptor (EGFR), and P04 downregulated oncoproteins such as Snail and Src. Importantly, P04 has no inhibitory effect on mesenchymal stem cells (MSCs). We also generated iTSCs by overexpressing ALDOA in MSCs and peripheral blood mononuclear cells (PBMCs). iTSC-derived conditioned medium (CM) inhibited the progression of PDAC cells as well as PDAC tissue fragments. The inhibitory effect of P04 was additive to that of CM and chemotherapeutic drugs such as 5-Flu and gemcitabine. Notably, applying mechanical vibration to PBMCs elevated ALDOA and converted PBMCs into iTSCs. Collectively, this study presented a unique procedure for selecting anticancer P04 from ALDOA in an iTSCs-derived proteome for the treatment of PDAC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available